RT Journal Article
T1 COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration.
A1 Hilbrands, Luuk B
A1 Duivenvoorden, Raphaël
A1 Vart, Priya
A1 Franssen, Casper F M
A1 Hemmelder, Marc H
A1 Jager, Kitty J
A1 Kieneker, Lyanne M
A1 Noordzij, Marlies
A1 Pena, Michelle J
A1 Vries, Hanne de
A1 Arroyo, David
A1 Covic, Adrian
A1 Crespo, Marta
A1 Goffin, Eric
A1 Islam, Mahmud
A1 Massy, Ziad A
A1 Montero, Nuria
A1 Oliveira, João P
A1 Roca Muñoz, Ana
A1 Sanchez, J Emilio
A1 Sridharan, Sivakumar
A1 Winzeler, Rebecca
A1 Gansevoort, Ron T
A1 ERACODA Collaborators, 
K1 COVID-19
K1 dialysis
K1 kidney
K1 mortality
K1 transplantation
AB Patients on kidney replacement therapy comprise a vulnerable population and may be at increased risk of death from coronavirus disease 2019 (COVID-19). Currently, only limited data are available on outcomes in this patient population. We set up the ERACODA (European Renal Association COVID-19 Database) database, which is specifically designed to prospectively collect detailed data on kidney transplant and dialysis patients with COVID-19. For this analysis, patients were included who presented between 1 February and 1 May 2020 and had complete information available on the primary outcome parameter, 28-day mortality. Of the 1073 patients enrolled, 305 (28%) were kidney transplant and 768 (72%) dialysis patients with a mean age of 60 ± 13 and 67 ± 14 years, respectively. The 28-day probability of death was 21.3% [95% confidence interval (95% CI) 14.3-30.2%] in kidney transplant and 25.0% (95% CI 20.2-30.0%) in dialysis patients. Mortality was primarily associated with advanced age in kidney transplant patients, and with age and frailty in dialysis patients. After adjusting for sex, age and frailty, in-hospital mortality did not significantly differ between transplant and dialysis patients [hazard ratio (HR) 0.81, 95% CI 0.59-1.10, P = 0.18]. In the subset of dialysis patients who were a candidate for transplantation (n = 148), 8 patients died within 28 days, as compared with 7 deaths in 23 patients who underwent a kidney transplantation  The 28-day case-fatality rate is high in patients on kidney replacement therapy with COVID-19 and is primarily driven by the risk factors age and frailty. Furthermore, in the first year after kidney transplantation, patients may be at increased risk of COVID-19-related mortality as compared with dialysis patients on the waiting list for transplantation. This information is important in guiding clinical decision-making, and for informing the public and healthcare authorities on the COVID-19-related mortality risk in kidney transplant and dialysis patients.
YR 2020
FD 2020
LK https://hdl.handle.net/10668/24389
UL https://hdl.handle.net/10668/24389
LA en
DS RISalud
RD Apr 5, 2025